Active regulatory T-cells contribute to broadened T-cell repertoire diversity in ivIg-treated SLE patients by Costa, Nuno et al.
POSTER PRESENTATION Open Access
Active regulatory T-cells contribute to broadened
T-cell repertoire diversity in ivIg-treated SLE
patients
Nuno Costa
1*, Ana E Pires
2, Ana M Gabriel
1, Luiz F Goulart
1, Clara Pereira
1,3, Barbara Leal
3, Ana C Queiros
2,
Wahiba Chaara
4, Maria F Moraes-Fontes
1,6, Carlos Vasconcelos
5, Carlos Ferreira
6, Jorge Martins
7, Marina Bastos
8,
Maria J Santos
9, Maria A Pereira
10, Berta Martins
3, Margarida Lima
5, Cristina João
2, Adrien Six
4,
Jocelyne Demengeot
1, Constantin Fesel
1
From 6th European Workshop on Immune-Mediated Inflammatory Diseases
Nice, France. 23-25 November 2011
Intravenous IgG (ivIg) is a therapeutic alternative for lupus
erythematosus. Relative oligoclonality of circulating T-cells
in SLE has been reported. Also CD4+Foxp3+ regulatory
T-cells (Tregs) have a characteristically reduced activity in
SLE, reflected by CD25 surface density. Aiming to study
the role of Tregs for ivIg therapy, we characterized Tregs
and determined TCR spectratypes of four Vb families with
reported oligoclonality, in 15 lupus patients (14 with SLE
and one with discoid LE) treated with ivIg in cycles of 2-6
consecutive monthly infusions. Among these 15 patients,
11 responded with clinical improvement. Cell counts,
cytometry and TCR spectratypes were obtained from per-
ipheral blood at various time points before, during and
after ivIg treatment. T-cell oligoclonality was assessed as
Vb-familywise repertoire perturbation, calculated for each
patient in respect to an individual reference profile aver-
aged over all available time points. For 11/15 patients,
average Vb1/Vb2/Vb11/Vb14 repertoires were less per-
turbed under ivIg treatment than outside ivIg therapy. The
four exceptions with relatively increased average perturba-
tion during ivIg therapy included three patients who failed
to respond clinically to an ivIg therapy cycle. Patients’
Treg CD25 surface density (cytometric MFI) was, other
than Treg/CD4+ frequency, clearly reduced when com-
pared to healthy controls, but not obviously influenced by
ivIg. However, patients’ average Treg CD25 MFI was
found negatively correlated with both Vb11 and Vb14 per-
turbations measured under ivIg therapy, which indicates a
role of active Tregs in the therapeutic effect of ivIg.
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